Core Safety Profile
Carboplatin

1. NAME OF THE MEDICINAL PRODUCT

4.2 Posology and method of administration

Carboplatin injection should be used by the intravenous route only.

The recommended dosage of carboplatin injection in previously untreated adult patients with normal kidney function is 400 mg/m² as a single intravenous dose administered by a 15- to 60-minute infusion. Therapy should not be repeated until 4 weeks after the previous carboplatin injection course and/or until the neutrophil count is at least 2,000 cells/mm³ and the platelet count is at least 100,000 cells/mm³.

Reduction of the initial dosage by 20-25% is recommended for those patients who present with risk factors such as prior myelosuppressive treatment and low performance status (ECOG-Zubrod 2-4 or Karnofsky below 80).

Determination of the hematologic nadir by weekly blood count during the initial courses of treatment with carboplatin injection is recommended for dosage adjustment for subsequent courses of therapy.

Needles or intravenous sets containing aluminum parts that may come in contact with carboplatin injection should not be used for preparation or administration. Aluminum reacts with carboplatin injection causing precipitate formation and/or loss of potency.

The safety measures for dangerous substances are to be complied with preparation and administration. Preparation must be carried out by personnel who have been trained in the safe use while wearing protective gloves, face mask and protective clothes.

Renal Impairment:
Patients with creatinine clearance values below 60 mL/min are at increased risk of severe myelosuppression. The frequency of severe leukopenia, neutropenia, or thrombocytopenia has been maintained at about 25% with the following dosage recommendations:

<table>
<thead>
<tr>
<th>Baseline Creatinine Clearance</th>
<th>Initial Dose (Day 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>41-59 mL/min</td>
<td>250 mg/m² I.V.</td>
</tr>
<tr>
<td>16-40 mL/min</td>
<td>200 mg/m² I.V.</td>
</tr>
</tbody>
</table>

Insufficient data exist on the use of carboplatin injection in patients with creatinine clearance of 15 mL/min or less to permit a recommendation for treatment.

All of the above dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient’s tolerance and to the acceptable level of myelosuppression.

Combination Therapy:
The optimal use of carboplatin injection in combination with other myelosuppressive agents requires dosage adjustments according to the regimen and schedule to be adopted.
Elderly patients
In patients of more than 65 years of age, adjustment of the carboplatin dose to the general condition is necessary during the first and the subsequent therapeutic courses.

Paediatric Patients:
There is insufficient information available to recommend a dosage in the paediatric population.

4.3 Contraindications
Carboplatin injection is contraindicated in:

- Hypersensitivity to carboplatin.
- Patients with pre-existing severe renal impairment (creatinine clearance < 30 mL/min), unless in the judgement of the physician and patient, the possible benefits of treatment outweigh the risks.
- Patients with severe myelosuppression.
- Patients with bleeding tumors.
- Concomitant use with yellow fever vaccine (see section 4.5.)

4.4 Special warnings and precautions for use
Carboplatin injection should be used only by physicians experienced with cancer chemotherapeutic drugs. Blood counts as well as renal and hepatic function tests must be done regularly and the drug should be discontinued if abnormal depression of the bone marrow or abnormal renal or hepatic function is seen.

Hematologic Toxicity:
Leukopenia, neutropenia, and thrombocytopenia are dose-dependent and dose-limiting. Peripheral blood counts should be monitored during carboplatin injection treatment frequently and, in case of toxicity, until recovery is achieved. Median day of nadir is day 21 in patients receiving single agent carboplatin injection and day 15 in patients receiving carboplatin injection in combination with other chemotherapeutic agents. In general, single intermittent courses of carboplatin injection should not be repeated until leukocyte, neutrophil, and platelet counts have returned to normal. Therapy should not be repeated until 4 weeks after the previous carboplatin injection course and/or until the neutrophil count is at least 2,000 cells/mm$^3$ and the platelet count is at least 100,000 cells/mm$^3$.

Anemia is frequent and cumulative requiring very rarely a transfusion.

Severity of myelosuppression is increased in patients with prior treatment (in particular with cisplatin) and/or impaired kidney function. Initial carboplatin injection dosages in these groups of patients should be appropriately reduced (see section 4.2) and the effects carefully monitored through frequent blood counts between courses. Carboplatin injection combination therapy with other myelosuppressive forms of treatment must be planned very carefully with respect to dosages and timing in order to minimize additive effects.

Allergic Reactions:
As with other platinum-based drugs, allergic reactions appearing most often during perfusion may occur and necessitate discontinuation of the perfusion and an appropriate symptomatic treatment. Cross reactions, sometimes fatal, have been reported with all the platinum compounds (see section 4.3 and section 4.8).

Renal toxicity
In patients with impaired renal function, the effect of carboplatin on the haematopoietic system is more pronounced and longer-acting than in patients with normal renal function. In this risk group, therapy with Carboplatin must be performed with special caution (see section 4.2 Posology and method of administration).

**Neurologic Toxicity:**
Although peripheral neurologic toxicity is generally common and mild, limited to paresthesia and decrease of osteotendinous reflexes, its frequency is increased in patients older than 65 years and/or in patients previously treated with cisplatin. Monitoring and neurological examinations should be carried out at regular intervals.

Visual disturbances, including loss of vision, have been reported after the use of carboplatin injection in doses higher than those recommended in patients with renal impairment. Vision appears to recover totally or to a significant extent within weeks of stopping these high doses.

**Geriatric Use:**
In studies involving combination therapy with carboplatin and cyclophosphamide, elderly patients treated with carboplatin were more likely to develop severe thrombocytopenia than younger patients. Because renal function is often decreased in the elderly, renal function should be considered when determining dosage (see section 4.2).

**Other:**
Auditory defects have been reported during carboplatin therapy. Ototoxicity may be more pronounced in children. Cases of hearing loss with a delayed onset have been reported in paediatric patients. A long-term audiometric follow-up in this population is recommended.

Administration of live or live-attenuated vaccines in patients immunocompromised by chemotherapeutic agents including carboplatin, may result in serious or fatal infections. Vaccination with a live vaccine should be avoided in patients receiving carboplatin. Killed or inactivated vaccines may be administered; however, the response to such vaccines may be diminished.

### 4.5 Interaction with other medicinal products and other forms of interaction

Due to the increase of thrombotic risk in case of tumoral diseases, the use of anticoagulative treatment is frequent. The high intra-individual variability of the coagulability during diseases, and the eventuality of interaction between oral anticoagulants and anticancer chemotherapy, require, if it is decided to treat the patient with oral anticoagulants, to increase frequency of the control of the INR monitoring.

**Concomitant use contraindicated**
- Yellow fever vaccine: risk of generalised vaccinal disease mortal ((see section 4.3.).

**Concomitant use not recommended**
- Live attenuated vaccines (except yellow fever): risk of systemic, possible fatal disease. This risk is increased in subjects who are already immunosuppressed by their underlying disease. Use an inactivated vaccine where this exist (poliomyelitis).

- Phenytoin, fosphenytoin Risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by the cytotoxic drug or risk of toxicity enhancement or lose of efficacy of the cytotoxic drug due to increased hepatic metabolism by phenytoin.

**Concomitant use to take into consideration**
- Cyclosporin (and by extrapolation tacrolimus and sirolimus): Excessive immunosuppression with risk of lymphoproliferation.
- Aminoglycosides: The concomitant use of carboplatine with aminoglycosides antibiotics should be taken into account due to the cumulative nephrotoxicity and ear toxicity, particularly in renal failure patient.
- Loop diuretics: The concomitant use of carboplatine with loop diuretic should be taken into account due to the cumulative nephrotoxicity and ear toxicity.

4.6 Pregnancy and lactation

Carboplatin injection can cause fetal harm when administered to a pregnant woman. Carboplatin injection has been shown to be embryotoxic and teratogenic in rats receiving the drug during organogenesis. No controlled studies in pregnant women have been conducted. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women with child-bearing potential should be advised to avoid becoming pregnant.

It is not known whether carboplatin injection is excreted in human milk. If treatment becomes necessary during the lactation period, breastfeeding must be stopped.

Fertility
Gonadal suppression resulting in amenorrhea or azospermia may occur in patients receiving antineoplastic therapy. These effects appear to be related to dose and length of therapy and may be irreversible. Prediction of the degree of testicular or ovarian function impairment is complicated by the common use of combinations of several antineoplastics, which makes it difficult to assess the effects of individual agents.

Men of sexually mature age treated with Carboplatin are recommended not to father a child during treatment and up to 6 month afterwards and to ask advice about spermatic preservation prior to initiation of the therapy because of the possibility of irreversible infertility due to therapy with carboplatin.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. However, Carboplatin may cause nausea, vomiting, vision abnormalities and ototoxicity; therefore, patients should be warned on the potential effect of these events on the ability to drive or to use machines.

4.8 Undesirable effects

The frequency of adverse reactions reported is based on a cumulative database of 1,893 patients receiving single agent carboplatin injection and post-marketing experience.

The list is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories: very common (≥1/10), common (≥1/100, < 1/10), uncommon (≥1/1000, <1/100), rare (≥1/10000, <1/1000), very rare (<1/10000), and not known (cannot be estimated from the available data).
<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency</th>
<th>MedDRA Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoplasms, benign and malignant(including cysts and polyps)</td>
<td>Not known</td>
<td>Treatment related secondary malignancy</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Common</td>
<td>Infections*</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Very common</td>
<td>Thrombocytopenia, neutropenia, leukopenia, anaemia</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Common</td>
<td>Haemorrhage*</td>
</tr>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>Not known</td>
<td>Bone marrow failure, febrile neutropenia, hemolytic-uraemic syndrome</td>
</tr>
<tr>
<td>Immune System Disorders</td>
<td>Common</td>
<td>Hypersensitivity, anaphylactoid type reaction</td>
</tr>
<tr>
<td>Metabolism and Nutrition Disorders</td>
<td>Not known</td>
<td>Dehydration, anorexia, hyponatraemia</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Common</td>
<td>Neuropathy peripheral, paraesthesia, decrease of osteotendinous reflexes, sensory disturbance, dysgeusia</td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>Not known</td>
<td>Cerebrovascular accident*</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Common</td>
<td>Visual disturbance</td>
</tr>
<tr>
<td>Ear and Labyrinth Disorders</td>
<td>Common</td>
<td>Rare cases of loss of vision</td>
</tr>
<tr>
<td>Cardiac Disorders</td>
<td>Common</td>
<td>Cardiovascular disorder*</td>
</tr>
<tr>
<td>Cardiac Disorders</td>
<td>Not known</td>
<td>Cardiac failure*</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td>Not known</td>
<td>Embolism*, hypertension, hypotension</td>
</tr>
<tr>
<td>Respiratory, Thoracic and Mediastinal Disorders</td>
<td>Common</td>
<td>Respiratory disorder, Interstitial lung disease, bronchospasm</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>Very common</td>
<td>Vomiting, nausea, abdominal pain</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>Common</td>
<td>Diarrhoea, constipation, mucous membrane disorder</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>Not known</td>
<td>Stomatitis</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td>Common</td>
<td>Alopecia, skin disorder</td>
</tr>
<tr>
<td>Skin and Subcutaneous Tissue Disorders</td>
<td>Not known</td>
<td>Urticaria, rash, erythema, pruritus</td>
</tr>
<tr>
<td>Musculoskeletal, Connective Tissue and Bone Disorders</td>
<td>Common</td>
<td>Musculoskeletal disorder</td>
</tr>
<tr>
<td>Renal and Urinary Disorders</td>
<td>Common</td>
<td>Urogenital disorder</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td>Common</td>
<td>Asthenia</td>
</tr>
<tr>
<td>General Disorders and Administration Site Conditions</td>
<td>Not known</td>
<td>Injection site necrosis, injection site reaction, injection site extravasation, injection site erythema, malaise</td>
</tr>
<tr>
<td>Investigations</td>
<td>Very Common</td>
<td>Creatinine renal clearance decreased, blood urea increased, blood alkaline phosphatase increased, aspartate aminotransferase increased, liver function test abnormal, blood sodium decreased, blood potassium decreased, blood calcium decreased, blood magnesium decreased.</td>
</tr>
<tr>
<td>Investigations</td>
<td>Common</td>
<td>Blood bilirubin increased, blood creatinine increased, blood uric acid increased</td>
</tr>
</tbody>
</table>

* Fatal in <1%, fatal cardiovascular events in <1% included cardiac failure, embolism, and cerebrovascular accident combined.

**Haematologic:**
Myelosuppression is the dose-limiting toxicity of carboplatin injection. In patients with normal baseline values, thrombocytopenia with platelet counts below 50,000/mm$^3$ occurs in 25% of patients, neutropenia with granulocyte counts below 1,000/mm$^3$ in 18% of patients, and leukopenia with WBC counts below 2,000/mm$^3$ in 14% of patients. The nadir usually occurs on day 21. Myelosuppression can be worsened by combination of carboplatin injection with other myelosuppressive compounds or forms of treatment.

Myelotoxicity is more severe in previously treated patients, in particular in patients previously treated with cisplatin and in patients with impaired kidney function. Patients with poor performance status have also experienced increased leukopenia and thrombocytopenia. These effects, although usually reversible, have resulted in infectious and hemorrhagic complications in 4% and 5% of patients given carboplatin injection, respectively. These complications have led to death in less than 1% of patients.

Anaemia with haemoglobin values below 8 g/dL has been observed in 15% of patients with normal baseline values. The incidence of anaemia is increased with increasing exposure to carboplatin injection.

**Gastrointestinal:**
Vomiting occurs in 65% of patients, in one-third of whom it is severe. Nausea occurs in an additional 15%. Previously treated patients (in particular patients previously treated with cisplatin) appear to be more prone to vomiting. These effects usually disappear within 24 hours after treatment and are generally responsive to or prevented by antiemetic medication. Vomiting is more likely when carboplatin injection is given in combination with other emetogenic compounds.

The other gastro-intestinal complaints corresponded to pain in 8% of patients, diarrhoea, and constipation in 6% of patients.

**Neurologic:**
Peripheral neuropathy (mainly paresthesias and decrease of osteotendinous reflexes) has occurred in 4% of patients administered carboplatin injection. Patients older than 65 years and patients previously treated with cisplatin, as well as those receiving prolonged treatment with carboplatin injection, appear to be at increased risk.

Clinically significant-sensory disturbances (ie, visual disturbances and taste modifications) have occurred in 1% of patients.

The overall frequency of neurologic side effects seems to be increased in patients receiving carboplatin injection in combination. This may also be related to longer cumulative exposure.

**Ototoxicity**
Auditory defects out of the speech range with impairments in the high-frequency range (4,000-8,000 Hz) were found in serial audiometric investigations with a frequency of 15%. Very rare cases of hypoacusia have been reported.

In patients with a hearing organ predamaged due to cisplatin, a further exacerbation in the hearing function sometimes occurs during treatment with carboplatin.

**Renal:**
When given in usual doses, development of abnormal renal function has been uncommon, despite the fact that carboplatin injection has been administered without high-volume fluid hydration and/or forced diuresis. Elevation of serum creatinine occurs in 6% of patients, elevation of blood urea nitrogen in 14%, and of uric acid in 5% of patients. These are usually mild and are reversible in about one-half the patients. Creatinine clearance has proven to be the most sensitive renal function measure in patients receiving carboplatin injection. Twenty-seven percent (27%) of patients who have a
baseline value of 60 mL/min or greater, experience a reduction in creatinine clearance during carboplatin injection therapy.

**Electrolytes:**
Decreases in serum sodium, potassium, calcium, and magnesium occur in 29%, 20%, 22%, and 29% of patients, respectively. In particular, cases of early hyponatraemia have been reported. The electrolyte losses are minor and mostly take a course without any clinical symptoms.

**Hepatic:**
Modification of liver function in patients with normal baseline values was observed, including elevation of total bilirubin in 5%, SGOT in 15%, and alkaline phosphatase in 24% of patients. These modifications were generally mild and reversible in about one-half the patients.
In a limited series of patients receiving very high dosages of carboplatin injection and autologous bone marrow transplantation, severe elevation of liver function tests has occurred.

Cases of an acute, fulminant liver cell necrosis occurred after high-dosed administration of carboplatin.

**Allergic Reactions:**
Anaphylactic-type reactions, sometimes fatal, may occur in the minutes following injection of the product: facial oedema, dyspnoea, tachycardia, low blood pressure, urticaria, anaphylactic shock, bronchospasm.

**Other undesirable effects:**
Secondary acute malignancies after cytostatic combination therapies containing carboplatin have been reported.

Alopecia, fever and chills, mucositis, asthenia, malaise as well as dysgeusia have occasionally been observed.

In isolated cases, a haemolytic-uraemic syndrome occurred.

Isolated cases of cardiovascular incidents (cardiac insufficiency, embolism) as well as isolated cases of cerebrovascular accidents have been reported.

Cases of hypertension have been reported.

**Local reactions:**
Reactions at the site of injection (burning, pain, reddening, swelling, urticaria, necrosis in connection with extravasation) have been reported.

### 4.9 Overdose

There is no known antidote for carboplatin injection overdosage. The anticipated complications of overdosage would be related to myelosuppression as well as impairment of hepatic and renal and auditory function. Use of higher than recommended doses of carboplatin injection has been associated with loss of vision (see section 4.4).